Conflict of interest
Y. Miyazaki received grants from Sumitomo-Dainippon, honoraria from Astellas, SynBio, Nippon-Shinyaku, Novartis, Abbvie, Sumitomo-Dainippon, Chugai; K. Ushiki received grants from Astellas Pharma, AbbVie, Apellis, SymBio, Daiichi-Sankyo, Novartis, Janssen, Otsuka, Astellas-Amgen-Biopharma, Takeda, Nippon-Shinyaku, Bristol-Myers-Squibb, Amgen, Alexion, Incyte, Ono, Kyowa-Kirin, Celgene, Sumitomo-Dainippon, Chugai, Pfizer, Mundi, Yakult, MSD, Gilead, and Nippon-Boehringer-Ingelheim, honoraria from Novartis, Bristol-Myers-Squibb, Sanofi, Pfizer, Abbvie, Takeda, Ono, Kyowa-Kirin, Astellas, Alexion, Eisai, MSD, Otsuka, Celgene, Daiichi-Sankyo, Nippon-Shinyaku, PharmaEssentia, Yakult, SymBio, Alexion, Chugai, and participation in Data Safety Monitoring for Takeda; I. Matsumura received grants from ONO PHARMACEUTICAL CO., LTD., Janssen Pharmaceutical K.K., NIPPON SHINYAKU CO.,LTD., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., TEIJIN PHARMA LIMITED., Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., MSD K.K., ASAHI KASEI PHARMA CORPORATION. Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., Japan Blood Products Organization., NIHON PHARMACEUTICAL CO., LTD, DAIICHI SANKYO COMPANY, LIMITED., AbbVie GK, TAIHO PHARMACEUTICAL CO., LTD., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., CSL Behring, Mundipharma K.K., AYUMI Pharmaceutical Corporation, Eli Lilly Japan K.K., Actelion Pharmaceuticals Japan Ltd., Amgen BioPharma K.K., consulting fee from Otsuka Pharmaceutical Co., Ltd., honoraria from Bristol-Myers Squibb (Celgene), Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, LIMITED., AbbVie GK, Amgen BioPharma K.K.; T. Maeda received grants from Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., Eisai Co., Ltd., Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc., honoraria from Nippon Shinyaku Co., Ltd., Bayer Yakuhin, Ltd., Novartis Pharmaceuticals; A. Tomita received grants from Chugai Pharmaceutical, Ono Pharmaceutical, Kyowa Kiri, Taiho Pharmaceutical, and honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical; H. Handa received grants from Nippon shinyaku, honoraria from Nippon Shinyaku; T. Yamiuchi received honoraria from Nippon Shinyaku; M. Ichikawa received consulting fee from Takeda Pharmaceuticals Co. Ltd.; T. Kiguchi received grants from Nippon Shinyaku Co., Ltd, honoraria from Nippon Shinyaku Co., Ltd; H. Kiyoi received grants from Nippon Shinyaku Co.; T. Naoe received support for the present manuscript from Astellas Pharma, Fuji Film, Daiichi Sankyo, honoraria from Sysmex, Bristol Myers Squibb, participation to Data Safety Monitoring for Nippon Shinyaku, Pfizer, Otsuka Pharma; T. Suzuki received grants from Abbie Inc, Kyowa Kirin Co.,Ltd, Nippon Shinyaku, honoraria from AbbVie Inc, Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Novartis Pharma K.K., Bristol-Myers Squibb, Ltd; S. Iyama received research funding from Sanofi, Alexion Pharmaceuticals, MSD, Otsuka, SynBio Pharmaceuticals, honoraria from Otsuka Pharmaceuticals Factory, Astellas Pharma, Alexion Pharmaceuticals, CSI Behring, Daiichi Sankyo, Meiji Pharma, Novartis, Nippon Shinyaku, Sanofi, SynBio Pharmaceuticals; S. Chiba received grants from Kyowa-Kirin, Chugai, Ono, Astellas, Eisai, Beyer. Other authors declared that there was no conflict of interest.